PFK-158 is a recently developed cancer drug that targets PFKFB3 to diminish glycolysis and decrease cell proliferation. PFK-158 has been shown to promote lipophagy, but it is not known whether this impacts other cell functions, such as migration. To look into this, we studied the impacts ofPFK-158 on MDCK cells and monitored migration and lipid droplet content. We found that migration was increased, while the number of lipid droplets decreased.